2 news · updated Jun 29, 2026

Merck to Buy Terns

2026-06-29

Merck Agrees to Acquire Bio-Techne for $11.3 Billion

Merck has agreed to acquire US life sciences firm Bio-Techne for $11.3 billion to bolster its portfolio in antibodies and cell therapy materials, with completion expected by 2027.

ccin · 2026-06-29 00:00 UTC

2026-03-25

Merck to Buy Terns in $6.7 Billion Deal

Merck & Co. agreed to acquire Terns Pharmaceuticals for $6.7 billion at $53 per share, representing a 31% premium, with the transaction expected to close within three months.

cen · 2026-03-25 00:00 UTC

Merck to Buy Terns

Merck Agrees to Acquire Bio-Techne for $11.3 Billion

Merck to Buy Terns in $6.7 Billion Deal

Media coverage (2)

Related topics